此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Digital Monitoring of Upper Limb Function in Non-Ambulant DMD (Acti-nRoll)

2026年6月18日 更新者:Laurent Servais、Centre Hospitalier Universitaire de Liege

Feasibility, Reliability, Clinical Validity and Sensitivity of Digital Outcomes to Monitor Upper Limb Function in Non-ambulant Patients With Genetically Confirmed Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder caused by the absence of dystrophin, leading to progressive muscle degeneration. Symptoms typically begin in early childhood and result in loss of ambulation by early adolescence, followed by cardiorespiratory complications. Although early treatment, including corticosteroids and emerging therapies, can slow disease progression, sensitive tools to monitor functional decline-particularly in non-ambulant patients-remain limited.

Current assessments rely primarily on clinical scales and hospital-based evaluations, which may not detect subtle changes or reflect real-life function. Digital outcome measures derived from wearable sensors offer a promising approach for continuous, objective monitoring in daily life. This study aims to evaluate the feasibility, reliability, clinical validity, and sensitivity of digital measures to assess upper limb function in non-ambulant patients with genetically confirmed DMD. The Syde device, previously validated in ambulant DMD patients, will be investigated for its applicability in this population.

研究概览

研究类型

介入性

注册 (估计的)

50

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Liège、比利时、4000
        • Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Patient with genetically confirmed Duchenne Muscular Dystrophy (DMD).
  • Non-ambulant at the time of inclusion (not able to walk 10m without external aid).
  • A legal guardian willing and able to provide written informed consent for participation in the study if < 18 years old.

Exclusion Criteria:

  • Any acute or chronic condition that, in the opinion of the investigator, may significantly interfere with the assessments and/or motor function progression.
  • Participation in an interventional clinical trial.
  • No access to internet connection or alternatively no capacity to come on-site to bring the Syde every 6 months after the recording periods for data retrieval by Liège team
  • Scoliosis surgery within the previous 6 months or planned within the next year

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Non-ambulant participants with Duchenne Muscular Dystrophy (DMD)
Syde是一种创新设备,旨在用于家庭环境中。 它由两个表格传感器组成,每个传感器都包含一个磁惯性传感器,该传感器记录了线性加速度,角速度,动作的磁场在各个方向上。两只手表可以作为手表或脚踝附近戴上。
将使用Myotools进行以下功能的最大力量的动力学测量:Palmar Grip(Myogrip)和Thumb-Index Pinch(Myopinch)。 测试将在主要方面实现。 在测试期间将鼓励患者。 他们将进行三个试验,并将输入最佳分数。
This test consists of a set of small manoeuvres (lifting a box, writing, etc.) designed to evaluate the upper-limb functionality of non-ambulatory patients. It was developed specifically for use in cases of Duchenne muscular dystrophy.
The Brooke Upper Extremity Functional Rating Scale will be used to assess the global functional level of upper limb involvement. This 6-point ordinal scale classifies patients according to their highest achievable upper limb function, from full arm abduction to absence of useful hand function.
Forced Vital Capacity (FVC) will be assessed using standardized spirometry procedures. The primary parameter will be FVC expressed as percentage of predicted values. At least three acceptable and reproducible maneuvers will be performed according to standard guidelines.
The CGI-S is a clinician-rated scale used at baseline to assess the overall severity of the participant's condition, based on all available clinical information. The rating reflects the clinician's judgment without standardized scoring rules and must be performed by a clinician experienced in Duchenne Muscular Dystrophy. The CGI-S evaluates three domains: physical motor function, respiratory function, and bulbar function. It is completed after all other study assessments (excluding patient-reported outcomes) to ensure a comprehensive evaluation.
The CGI-C is used at each follow-up visit to assess changes in the participant's condition relative to baseline. It provides a clinician-determined measure of improvement or worsening, based on overall clinical judgment rather than fixed criteria. Like the CGI-S, it covers physical motor, respiratory, and bulbar domains and is performed after all other study assessments (excluding patient-reported outcomes). The CGI-C is expected to track consistently with prior CGI-S evaluations, reflecting changes in disease status over time.
The PGI-S (Patient Global Impression of Severity) is a simple, validated, single-item self-administered scale used to assess the current severity of a patient's condition. Widely used in clinical trials, it allows patients to rate their condition, on a 4- to 6-point scale (from 'Normal' to 'Very severe').

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Device usage (recording time)
大体时间:Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24
Total recording time per recording period (hours)
Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24
Patient compliance (Min)
大体时间:Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24
Percentage of participants achieving minimal threshold (expected 50h) of recording time per period
Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24
Patient compliance (Max)
大体时间:Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24
Percentage of participants achieving optimal threshold (expected 180h) of recording time per period
Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24

次要结果测量

结果测量
措施说明
大体时间
Reliability
大体时间:Baseline, Month 6, Month 12, Month 18, Month 24
Intraclass Correlation Coefficient (ICC) for two distinct consecutive half-periods
Baseline, Month 6, Month 12, Month 18, Month 24
Clinical validity of digital outcome vs Brooke
大体时间:Baseline, Month 6, Month 12, Month 18, Month 24
Correlation between digital outcome and Brooke Upper Extremity Rating Scale (Brooke score)
Baseline, Month 6, Month 12, Month 18, Month 24
Clinical validity of digital outcome vs PUL
大体时间:Baseline, Month 6, Month 12, Month 18, Month 24
Correlation between digital outcome and Performance of Upper Limb (PUL) score
Baseline, Month 6, Month 12, Month 18, Month 24
Sensitivity of Digital Upper Limb Outcome Measures
大体时间:Baseline, Month 6, Month 12, Month 18, Month 24
Sensitivity will be evaluated by assessing the ability of digital outcome measures to detect change over time combining mean change from baseline, slope of change over time, and standardized response mean (SRM).
Baseline, Month 6, Month 12, Month 18, Month 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Laurent Servais, MD、Centre Hospitalier Universitaire de Liege

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年7月30日

初级完成 (估计的)

2029年6月30日

研究完成 (估计的)

2030年4月30日

研究注册日期

首次提交

2026年6月15日

首先提交符合 QC 标准的

2026年6月18日

首次发布 (实际的)

2026年6月23日

研究记录更新

最后更新发布 (实际的)

2026年6月23日

上次提交的符合 QC 标准的更新

2026年6月18日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅